文献速递疼痛医学

运动皮层重复经颅磁刺激治疗纤维肌痛:多中心随机对照试验

Motor cortex repetitive transcranial magnetic stimulation in fibromyalgia: a multicentre randomised controlled trial.
PubMed 文献 · Br J Anaesth · 2025-03-13

这项国际随机双盲假对照试验纳入101名难治性纤维肌痛女性,评估10 Hz运动皮层rTMS作为附加疗法的疗效。第8周时活动组≥50%疼痛缓解的贝叶斯概率为99.4%(OR 3.04;95% CrI 1.26-8.06),NNT为4.54,相对疼痛缓解优于假组(40.4% vs 18.4%,P=0.028)。第16周镇痛效应减弱,但功能改善仍持续。

要点

  • 附加M1-rTMS可使难治性纤维肌痛女性在第8周疼痛缓解≥50%的概率达99.4%。
  • 第8周活动组相对疼痛缓解40.4%,假组18.4%(P=0.028),NNT为4.54。
  • 第16周镇痛效应减弱(OR 0.815;95% CrI 0.313-2.1),但FIQ评分降低可能性为79.1%。

核心结论

  • 附加M1-rTMS在难治性纤维肌痛女性中减轻疼痛强度至第8周,镇痛效应随后减弱但功能改善在第16周延长维持期仍持续。

研究设计与样本

  • 国际多中心随机双盲假对照试验,在巴西、法国和日本纳入101名≥18岁难治性纤维肌痛女性,随机分入活动组(n=52)或假组(n=49)。
  • 干预为10 Hz运动皮层rTMS,每日3000脉冲,包括2周内10次诱导治疗、6周每周维持治疗和8周每两周延长维持治疗。

主要发现

  • 第8周活动组较假组≥50%疼痛缓解的贝叶斯概率为99.4%(OR 3.04;95% CrI 1.26-8.06),NNT为4.54。
  • 频率派分析显示活动组相对疼痛缓解高于假组(40.4% vs 18.4%,P=0.028)。
  • 第16周≥50%疼痛缓解概率降至34.2%(OR 0.815;95% CrI 0.313-2.1),但FIQ评分降低的可能性为79.1%。
  • 干预看起来安全。

关键数值与推荐

  • 主要结局为第8周较基线≥50%疼痛缓解。
  • 次要结局包括第8周和第16周的疼痛干扰、情绪、总体变化印象和纤维肌痛影响问卷(FIQ)评分。

临床怎么用

  • 对于最佳可用治疗难治的纤维肌痛女性,可考虑将10 Hz M1-rTMS作为附加治疗以短期减轻疼痛强度。
  • 需告知患者镇痛效应可能在第8周后减弱,但功能改善可能维持至第16周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite affecting 2-4% of the population worldwide, fibromyalgia often remains refractory to treatment. Here we report the first international randomised double-blind, sham-controlled trial developed to assess the efficacy of repetitive transcranial magnetic stimulation (rTMS) as an add-on therapy for fibromyalgia. METHODS: Women aged ≥18 yr with fibromyalgia refractory to best available treatment were enrolled in Brazil, France, and Japan, and randomised to 10 Hz motor cortex (M1) rTMS, 3000 pulses day-1, or sham stimulation. This included 10 induction sessions over 2 weeks, followed by weekly maintenance (6 weeks), and fortnightly extended maintenance (8 weeks). Primary outcome was ≥50% pain reduction at week 8 compared with baseline. Secondary outcomes included pain interference, mood, global impression of change, and Fibromyalgia Impact Questionnaire (FIQ) scores at weeks 8 and 16. RESULTS: We randomised 101 women (mean age 48 [range 25-83] yr) into active (n=52) or sham (n=49) arms. Bayesian analysis revealed a 99.4% probability of ≥50% pain reduction at week 8 in the active group vs sham (odds ratio [OR] 3.04; 95% credible interval [95% CrI] 1.26-8.06), with a number needed to treat of 4.54. Frequentist analysis confirmed that relative pain reduction was higher in the active than in the sham group (40.4% vs 18.4%, P=0.028). At week 16, this probability reduced to 34.2% (OR 0.815; 95% CrI 0.313-2.1), but the likelihood of FIQ score reduction was 79.1%. The intervention appeared safe. CONCLUSIONS: Add-on M1-repetitive transcranial magnetic stimulation reduced pain intensity up to 8 weeks in women with fibromyalgia. Although analgesic effects waned, functional improvements remained during extended maintenance at week 16.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Silva VA, Baptista AF, Fonseca AS, et al. Motor cortex repetitive transcranial magnetic stimulation in fibromyalgia: a multicentre randomised controlled trial. Br J Anaesth. 2025. PMID: 40087077. doi:10.1016/j.bja.2024.12.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。